Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Rhea-AI Summary

Nanobiotix, listed on Euronext Paris and Nasdaq (NBTX), has reported its outstanding shares as of March 31, 2022, at 34,875,872. The total voting rights stood at 36,317,823 gross and 36,304,866 net. The company is pioneering physics-based therapeutic approaches, notably in oncology with its lead product, NBTXR3, which has secured market authorization in Europe for soft tissue sarcoma treatment under the brand name Hensify®.

For further details, visit www.nanobiotix.com.

Positive

• Total voting rights reported at 36,317,823 gross and 36,304,866 net.
• Lead product NBTXR3 has received market authorization in Europe for soft tissue sarcoma.

Negative

• None.

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)

PARIS--(BUSINESS WIRE)-- Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.P
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights
		Total voting rights, gross (1)	Total voting rights, net (2)
Mars 31, 2022	34,875,872	36,317,823	36,304,866

⁽¹⁾ The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

⁽²⁾ The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.

***

About NANOBIOTIX: http://www.nanobiotix.com
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on the regulated market of Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company's resources are primarily devoted to the development of its lead product candidate– NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220407005709/en/

Nanobiotix

Nanobiotix Communications

Brandon Owens

VP, Communications

+1 (617) 852-4835

contact@nanobiotix.com

Nanobiotix Investor Relations

Kate McNeil

SVP, Investor Relations

+1 (609) 678-7388

investors@nanobiotix.com

Media Relations

France – Ulysse Communication

Pierre-Louis Germain

+ 33 (0) 6 64 79 97 51

plgermain@ulysse-communication.com

US – Porter Novelli

Dan Childs

+1 (781) 888-5106

dan.childs@porternovelli.com

Source: Nanobiotix

FAQ

What is the total number of shares outstanding for Nanobiotix as of March 31, 2022?

As of March 31, 2022, Nanobiotix has 34,875,872 shares outstanding.

How many total voting rights does Nanobiotix hold?

Nanobiotix's total voting rights are reported as 36,317,823 gross and 36,304,866 net as of March 31, 2022.

What product has Nanobiotix received market authorization for?

Nanobiotix's lead product, NBTXR3, has market authorization in Europe for the treatment of soft tissue sarcoma.

On which stock exchanges is Nanobiotix listed?

Nanobiotix is listed on Euronext Paris and Nasdaq under the ticker symbol NBTX.